Lilly Launches Foundayo in the UK as NICE Review Continues

insidermonkey.com · 2026-09-05

Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment for weight management and type 2 diabetes is...

TickrTrends take: Lilly's UK launch of Foundayo while NICE conducts its review introduces timing considerations for European revenue recognition that investors focused on valuation should monitor closely. The regulatory pathway in the UK market could influence the company's ability to capture near-term sales in a major developed market, which bears relevance to current earnings projections underlying the Undervalued assessment. Given Healthcare sector cyclicality and the dependency of valuations on successful product commercialization, the NICE determination will be a key datapoint for validating whether the current valuation thesis holds or requires recalibration.

Read the full story at insidermonkey.com →